Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3), a pooled analysis of 10,000 cases and 11,000 controls, found that genetic variants near CYP24A1 were associated with a decreased risk of aggressive prostate cancer (p trend <0.001), and a score made of four genes thought to predict circulating levels of 25(OH)D (VDBP, CYP24A1, CYP2R1, DHCR7) was related to both overall and aggressive prostate cancer [38]. Here, GC is linked to prostate cancer.